Dominari Holdings Inc. (NASDAQ:DOMH) Short Interest Up 578.3% in April

Dominari Holdings Inc. (NASDAQ:DOMH) was the target of a significant growth in short interest during the month of April. As of April 15th, there was short interest totalling 15,600 shares, a growth of 578.3% from the March 31st total of 2,300 shares. Approximately 0.3% of the company’s shares are sold short. Based on an average daily volume of 12,300 shares, the short-interest ratio is currently 1.3 days.

Dominari Price Performance

Shares of NASDAQ DOMH remained flat at $2.70 during mid-day trading on Friday. 16,313 shares of the company traded hands, compared to its average volume of 18,784. The business’s 50-day moving average price is $2.41 and its 200 day moving average price is $2.26. Dominari has a 12 month low of $1.76 and a 12 month high of $3.67.

Dominari (NASDAQ:DOMH) last released its quarterly earnings data on Monday, April 1st. The company reported ($1.28) earnings per share (EPS) for the quarter. The business had revenue of $1.01 million for the quarter.

Insiders Place Their Bets

In related news, President Kyle Michael Wool acquired 8,500 shares of the firm’s stock in a transaction dated Monday, April 8th. The shares were purchased at an average price of $2.99 per share, for a total transaction of $25,415.00. Following the completion of the acquisition, the president now owns 22,750 shares in the company, valued at $68,022.50. The purchase was disclosed in a filing with the SEC, which is available at this link. Insiders acquired 31,444 shares of company stock valued at $90,278 over the last three months. Insiders own 9.74% of the company’s stock.

Dominari Company Profile

Dominari Holdings Inc, a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia.